Trelagliptin inhibits IL-1β-induced MCP-1 expression in human aortic endothelial cells by inhibiting the NF-κB pathway, preventing monocyte infiltration during atherosclerosis (Meng et al., 2020). This evidence concerns the gene NFKB1 and atherosclerosis.